? Clear Development Path Forward for XRx-101 ? ? Clear Development Path Forward for XRx-101 ?
Excerpt from:
XORTX Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury
Orphazyme A/SCompany announcement No. 64/2020 Company Registration No. 32266355
Bagsværd, Denmark, 8 October 2020 – Novo Nordisk today announced that the full-year sales and operating profit outlook at constant exchange rates (CER) has been raised.
See original here:
Novo Nordisk raises sales and operating profit outlook for 2020
ROCKVILLE, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) -- American Gene Technologies (AGT) a cutting-edge cell and gene therapy company in Rockville, Maryland announced today that CEO Jeff Galvin will present at the annual Cell & Gene Meeting on the Mesa. The meeting will be held virtually October 12-16. Galvin’s presentation will highlight the company's technology, including AGT103-T, a therapeutic intended to cure HIV, which is scheduled to begin Phase 1 clinical trials this month.
Follow this link:
American Gene Technologies to Present at 2020 Virtual Cell & Gene Meeting on the Mesa
Monthly information regarding the total number of voting rights and
See original here:
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2020
Ali Behbahani, M.D. takes on role of Chairperson of the Board
See the article here:
Oyster Point Pharma Announces Board of Directors Leadership Changes and New Appointment as the Company Advances into Next Phase of Growth
Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth
Read this article:
GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020
Application of ImmTOR™ plus IGAN’s IgA protease to target immunoglobulin A (IgA) deposition, the critical event leading to IgA Nephropathy (IgAN)
Go here to see the original:
Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in...
Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season
Read more:
GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) Receives EUA from FDA
VALENCIA, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- SetPoint Medical, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel bioelectronic device for patients with rheumatoid arthritis (RA) who have incomplete response to, or are intolerant to multiple biologic drugs. The Company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases, and is initially focused on the treatment of RA as a potentially efficacious, yet less immunosuppressive option.
Read the original here:
SetPoint Medical Receives FDA Breakthrough Device Designation for its Novel Bioelectronic Platform